All In MedTech

FDA Clearance Tracker · P130008-S090

Inspire Upper Airway Stimulation System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 8, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 8, 2023

Approved

Time to decision

234 days

Received Oct 17, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130008-S090
Device name
Inspire Upper Airway Stimulation System
Applicant location
Maple Grove, MN
Received
Oct 17, 2022
Decided
Jun 8, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130008

Device type

Device class
Class III

Every decision under product code MNQ

FDA's approval statement

As written in FDA's record.

Approval to expand the indications for use to OSA patients with an upper limit baseline apnea-hypopnea index (AHI) to 100 (increase from <= 65 to <=100) and increasing the an upper limit body mass index (BMI) warning to 40 (increase from <=32 to <=40).

Source documents

Other decisions for Inspire Medical Systems

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.